Achievement of response over time with fremanezumab in the treatment of chronic and episodic migraine (vol 19, pg P11, 2018)

被引：0
|
作者：
Silberstein, Stephen D. [1 ]
Lipton, Richard B. [2 ]
Diamond, Merle L. [3 ]
Cohen, Joshua M. [4 ]
Yang, Ronghua [4 ]
Jiang, Bo [4 ]
机构：
[1] Thomas Jefferson Univ, Jefferson Headache Ctr, Philadelphia, PA 19107 USA
[2] Albert Einstein Coll Med, Bronx, NY 10467 USA
[3] Diamond Headache Clin Ltd, Chicago, IL USA
[4] Teva Pharmaceut, Frazer, PA USA
来源：
JOURNAL OF HEADACHE AND PAIN | 2018年 / 19卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页数：2
相关论文
共 39 条
  • [21] Long-term impact of fremanezumab on response rates, acute headache medication use, and disability in patients with episodic migraine: interim results of a 1-year study (vol 19, P5, 2018)
    Brandes, Jan L.
    Yeung, Paul P.
    Cohen, Joshua M.
    Gandhi, Sanjay K.
    Fitzgerald, Timothy
    Yang, Ronghua
    Ma, Yuju
    Aycardi, Ernesto
    JOURNAL OF HEADACHE AND PAIN, 2018, 19
  • [22] Elevation of p11 in lateral habenula mediates depression-like behavior (vol 23, pg 1113, 2018)
    Seo, J-S.
    Zhong, P.
    Liu, A.
    Yan, Z.
    Greengard, P.
    MOLECULAR PSYCHIATRY, 2020, 25 (12) : 3451 - 3452
  • [23] Efficacy and safety of fremanezumab in patients with episodic and chronic migraine with documented inadequate response to 2 to 4 classes of migraine preventive medications over 6 months of treatment in the phase 3b FOCUS study
    Ashina, Messoud
    Cohen, Joshua M.
    Galic, Maja
    Campos, Verena Ramirez
    Barash, Steve
    Ning, Xiaoping
    Kessler, Yoel
    Janka, Lindsay
    Diener, Hans-Christoph
    JOURNAL OF HEADACHE AND PAIN, 2021, 22 (01)
  • [24] Efficacy and safety of fremanezumab in patients with episodic and chronic migraine with documented inadequate response to 2 to 4 classes of migraine preventive medications over 6 months of treatment in the phase 3b FOCUS study
    Messoud Ashina
    Joshua M. Cohen
    Maja Galic
    Verena Ramirez Campos
    Steve Barash
    Xiaoping Ning
    Yoel Kessler
    Lindsay Janka
    Hans-Christoph Diener
    The Journal of Headache and Pain, 2021, 22
  • [25] 10-YEAR COST-EFFECTIVENESS ANALYSES OF FREMANEZUMAB COMPARED TO NO TREATMENT AS A PREVENTIVE TREATMENT IN CHRONIC AND EPISODIC MIGRAINE FOR PATIENTS WITH INADEQUATE RESPONSE TO PRIOR PREVENTIVE TREATMENTS
    Smolen, L.
    Gandhi, S. K.
    Klein, T.
    Thompson, S.
    Cohen, J.
    VALUE IN HEALTH, 2019, 22 : S743 - S743
  • [26] Chronic tonsillitis and biofilms: a brief overview of treatment modalities (vol 11, pg 329, 2018)
    Abu Bakar, M.
    McKimm, J.
    Haque, S. Z.
    Majumder, M. A. A.
    Haque, M.
    JOURNAL OF INFLAMMATION RESEARCH, 2018, 11 : 375 - 375
  • [27] Evaluation of OnabotulinumtoxinA Treatment in Patients with Concomitant Chronic Migraine and Temporomandibular Disorders (vol 55, pg 330, 2018)
    Kocaman, Gulsen
    Kahraman, Nese
    Gurkan Koseoglu, Banu
    Bilgic, Basar
    Matur, Zeliha
    Ertas, Mustafa
    Gulsen, Yesim
    Baykan, Betul
    NOROPSIKIYATRI ARSIVI-ARCHIVES OF NEUROPSYCHIATRY, 2019, 56 (01): : 83 - 83
  • [28] Overview of fremanezumab pooled safety data from placebocontrolled phase 2 and 3 studies (vol 19, pg P6, 2018)
    Silberstein, Stephen D.
    Faulhaber, Nicola
    Ning, Xiaoping
    Yeung, Paul P.
    Schiemann, Jimmy
    Yang, Ronghua
    Ma, Yuju
    Aycardi, Ernesto
    JOURNAL OF HEADACHE AND PAIN, 2018, 19
  • [29] 10-YEAR COST-EFFECTIVENESS ANALYSES OF RESPONSE-BASED USE OF FREMANEZUMAB AS PREVENTIVE TREATMENT IN CHRONIC AND EPISODIC MIGRAINE FOR PATIENTS WITH INADEQUATE RESPONSE TO PRIOR PREVENTIVE TREATMENTS
    Smolen, L.
    Thompson, S.
    Klein, T.
    Cohen, J.
    Gandhi, S. K.
    VALUE IN HEALTH, 2019, 22 : S743 - S743
  • [30] Omalizumab chronic spontaneous urticaria: Efficacy, safety, predictors of treatment outcome, and time to response (vol 121, pg 474, 2018)
    Nettis, E.
    Cegolon, L.
    Di Leo, E.
    Rizzini, Lodi F.
    Detoraki, A.
    Canonica, G. W.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2018, 121 (06) : 749 - 749
1234